Ligand Pharmaceuticals’ Zelsuvmi Receives the US FDA’s Approval for the Treatment of Molluscum Contagiosum
Shots:
- Zelsuvmi (berdazimer topical gel, 10.3%) received the US FDA’s approval as a novel drug for the treatment of molluscum infections in adults & pediatric patients aged ≥1yrs. Zelsuvmi is expected to be commercially available in the US by H2’24
- The company evaluated the safety & effectiveness of the US FDA-approved Zelsuvmi in P-III clinical trials (B-SIMPLE 4) & (B-SIMPLE 2) among patients (n=1,598) with Molluscum Contagiosum that depicted Zelsuvmi’s ability to reduce lesion counts & was well tolerated as QD dosage in patients
- Zelsuvmi is a nitric oxide (NO) releasing agent that has been attributed to have antiviral properties. With unknown mechanism of action of Zelsuvmi will be used as a tropical treatment in patients above age of 1year (pediatric & adults)
Ref: Ligand Pharmaceuticals | Image: Ligand Pharmaceuticals
Related News:- Palvella Therapeutics Expands Partnership with Ligand Pharmaceuticals to Accelerate P-III development of Qtorin Rapamycin
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
